Compare AVLN & PSNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVLN | PSNY |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2026 | 2021 |
| Metric | AVLN | PSNY |
|---|---|---|
| Price | $27.52 | $6.27 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 4 | 3 |
| Target Price | ★ $62.25 | $12.50 |
| AVG Volume (30 Days) | 192.8K | ★ 291.6K |
| Earning Date | 08-12-2026 | 09-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $3.84 |
| Revenue Next Year | N/A | $35.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.90 | $0.50 |
| 52 Week High | $40.17 | $23.75 |
| Indicator | AVLN | PSNY |
|---|---|---|
| Relative Strength Index (RSI) | 35.91 | 20.44 |
| Support Level | $25.86 | N/A |
| Resistance Level | $30.45 | $8.15 |
| Average True Range (ATR) | 2.25 | 0.38 |
| MACD | -0.56 | 0.10 |
| Stochastic Oscillator | 14.12 | 0.81 |
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Polestar Automotive Holding UK PLC is a pure play, premium electric car brand, designing performance cars engineered to excite consumers and drive change. It believes that it defines market standards in design, innovation and sustainability. It is determined to improve society by accelerating the shift to sustainable mobility. The company conducts its business as one operating segment with primary commercial operations in Europe, North America, Asia Pacific and various importer markets. The company generates majority of revenue from United Kingdom.